Enhancement ratio | Mean | 95 % confidence interval | P value (RC) | P value (NRC) | P value (NRC 1.5 T) | P value (NRC 3.0 T) |
Non-rheumatologic control (48) | 0.138 | −0.063 – 0.339 | 1.00 | - | – | – |
Rheumatologic control (66) | 0.112 | 0.011 – 0.213 | – | 1.00 | 0.06 | 0.16 |
Mild (53) | 0.592 | 0.380 – 0.804 | 0.0008 | 0.005 | 0.96 | <0.0001 |
Moderate/severe (15) | 1.284 | 0.827 – 1.740 | <0.0001 | <0.0001 | 0.007 | <0.0001 |
Relative signal intensity change | Mean | 95 % confidence interval | P value (RC) | P value (NRC) | P value (NRC 1.5 T) | P value (NRC 3.0 T) |
Non–rheumatologic control (48) | 0.588 | 0.391 – 0.785 | <0.0001 | – | – | – |
Rheumatologic control (66) | 0.008 | −0.097 – 0.113 | – | <0.0001 | 0.01 | <0.0001 |
Mild (53) | 0.470 | 0.267 – 0.673 | 0.001 | 1.00 | 1.00 | 0.26 |
Moderate/severe (15) | 0.951 | 0.542 – 1.360 | <0.0001 | 0.35 | 0.07 | 0.51 |